Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer

NCT05645094 | Not Yet Recruiting

• 1 other identifier: FDCRC85LXX
• Study Type: observational
• Target: 38
• Locations: 0 countries
• Sites: N/A

Brief Summary

This is a single center, prospective, single arm clinical trial to evaluate the efficacy and safety of Envafolimab as a neoadjuvant therapy for resectable and locally advanced dMMR or MSI-H rectal cancer.

Conditions

Locally Advanced Rectal Carcinoma; MSI-High

Outcome Measures

Primary Outcomes (1)

• cCR and pCR rates

  Complete clinical response rate (cCR) after neoadjuvant therapy or complete pathological response rate (pCR) of patients undergoing surgery

  1-year

Secondary Outcomes (7)

• Tumor regression grade (TRG)

  1-year

• Objective response rate (ORR)

  1-year

• local regrowth rate after cCR

  3-year

• 3-year relapse-free survival

  3-year

• 3-year overall survival

  3-year

Interventions

Envafolimab DRUG

Patients will receive single drug therapy of Envafolimab (300mg) once every two weeks. Patients who do not have tumor regression after 3 months of treatment should be judged by the investigator whether to adopt standard chemoradiotherapy plus surgery. Patients with tumor regression should continue to receive Envafolimab therapy until 6 months. For patients who do not reach complete clinical response (cCR) after 6 months of treatment, the investigator shall determine whether to perform standard chemoradiotherapy or radical surgery. For patients who reach cCR, they could receive the observation waiting or local resection which depend on the investigator. Patients should be followed up until reaching cCR or 3 years after surgery.

Eligibility Criteria

• Age: 18 Years - 79 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Resectable locally advanced dMMR or MSI-H rectal cancer.

You may qualify if:

• Subjects volunteer to join the study and could complete the signing of the informed consent form, and had good compliance;
• Age ≥ 18 years old and\<80 years old (when signing the informed consent form);
• ECOG score 0-1;
• Resectable rectal cancer was confirmed by pathological diagnosis (pathology/cytology) and imaging;
• The clinical TNM stage is T3-4N0M0 or TanyN+M0;
• The distance from the lower edge of the tumor to the lower edge of the anus is ≤ 10cm;
• Patients who need routine neoadjuvant therapy after evaluation;
• dMMR or MSI-H was detected by immunohistochemistry/PCR;
• Patients did not received immunotherapy, chemotherapy, targeted therapy or radiotherapy for rectal cancer in the past;
• The expected life span exceeds 3 months;
• It has measurable lesions (according to iRECIST standard, the long diameter of CT scan for non lymph node lesions is ≥ 10 mm, and the short diameter of CT scan for lymph node lesions is ≥ 15 mm);
• The function of main organs is normal, they should meet the following standards:
• Blood routine examination: Absolute Neutrophil Count (ANC) 1.5 × 109/L, Platelet (PLT) ≥ 70 × 109/L, Hemoglobin (HGB) ≥ 90 g/L;
• Liver function: total bilirubin (TBIL) ≤ 1.5 × Upper Limit of Normal Value (ULN); Alanine Aminotransferase (ALT) and Aspartate Transferase (AST) ≤ 3 × ULN; Serum albumin ≥ 28 g/L; Alkaline phosphatase (ALP) ≤ 5 × ULN; After routine liver protection treatment, it meets the above criteria, and can be stable for at least 1 week. After evaluation by the researcher, it can be included in the group;
• Renal function: serum creatinine (Cr) ≤ 1.5 × ULN, or creatinine clearance ≥ 50 mL/mi (using the standard Cockcroft Gault formula);

You may not qualify if:

• Patients with active autoimmune diseases or autoimmune diseases that may recur are as follows, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism, and those who have previously undergone thyroid surgery cannot be included; Subjects who suffer from vitiligo or asthma in childhood has completely alleviated, and do not need any intervention after adulthood can be included; Asthma requiring medical intervention with bronchodilators was excluded;
• Subjects with any severe and/or uncontrollable disease. include:
• Poor blood pressure control (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg);
• Suffering from ≥ grade 2 myocardial ischemia or myocardial infarction, arrhythmia (QTc ≥ 470ms) and ≥ grade 2 congestive heart failure (NYHA classification);
• Renal failure requiring hemodialysis or peritoneal dialysis;
• Have a history of immunodeficiency, including HIV positive or other acquired or congenital immunodeficiency diseases, or have a history of organ transplantation;
• Poor control of diabetes (fasting blood glucose \[FBG\]\>10mmol/L);
• Those who received major surgical treatment, open biopsy or obvious traumatic injury within 28 days before the start of the study treatment; Or there is a wound or fracture that has not been cured for a long time;
• Serious arteriovenous thrombotic events occurred within 6 months before the study treatment, such as cerebrovascular accident (including temporary ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism;
• Those who have a history of abuse of psychotropic substances and are unable to quit or have mental disorders;
• Tumor related symptoms and treatment:
• Within 3 weeks before the start of the study treatment, he had received surgery, chemotherapy, small molecule targeted therapy, radiotherapy or other anti-tumor therapy (washout period is calculated from the end time of the last treatment).
• Within 2 weeks before the start of the study, those who have received the treatment of Chinese patent drugs with anti-tumor indications specified in the NMPA approved drug manual (including compound cantharis capsule, Kangai injection, Kanglaite capsule/injection, Aidi injection, Brucea javanica oil injection/capsule, Xiaoaiping tablet/injection, cinobufagin capsule, etc.);
• Uncontrolled pleural effusion, pericardial effusion or ascites that still need repeated drainage (judged by the investigator);
• Study treatment related:

Sponsors & Collaborators

• Fudan University: lead

MeSH Terms

Interventions

envafolimab

Study Officials

• Xinxiang Li, MD

  Fudan University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Yaqi Li, PhD

CONTACT

+8615902194450; yaqili702@hotmail.com

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: December 1, 2022
• First Posted: December 9, 2022
• Study Start: January 1, 2023
• Primary Completion: June 1, 2023
• Study Completion (Estimated): June 1, 2026
• Last Updated: December 13, 2022

Record last verified: 2022-12

Data Sharing

• IPD Sharing: Will not share